Phase I trial outcomes in older patients with advanced solid tumours

about

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

P2860

Q36303802-3E91AA58-254A-43DA-8517-1FD2A750F3E3 Q47990284-25F4E140-0F5B-44EC-BAD2-D639C4C047B7

P2860

Phase I trial outcomes in older patients with advanced solid tumours

Item

http://www.wikidata.org/entity/Q36547934

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase I trial outcomes in older patients with advanced solid tumours

@ast

Phase I trial outcomes in older patients with advanced solid tumours

@en

type

Item

label

Phase I trial outcomes in older patients with advanced solid tumours

@ast

Phase I trial outcomes in older patients with advanced solid tumours

@en

prefLabel

Phase I trial outcomes in older patients with advanced solid tumours

@ast

Phase I trial outcomes in older patients with advanced solid tumours

@en

P1476

Phase I trial outcomes in older patients with advanced solid tumours

@en

P2093

A Ring

http://www.w3.org/2001/XMLSchema#string

A Smith

http://www.w3.org/2001/XMLSchema#string

A Zivi

http://www.w3.org/2001/XMLSchema#string

I Judson

http://www.w3.org/2001/XMLSchema#string

J S de Bono

http://www.w3.org/2001/XMLSchema#string

K H Khan

http://www.w3.org/2001/XMLSchema#string

K Thomas

http://www.w3.org/2001/XMLSchema#string

L R Molife

http://www.w3.org/2001/XMLSchema#string

S B Kaye

http://www.w3.org/2001/XMLSchema#string

S Bodla

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Understanding the attitudes of the elderly towards enrolment into cancer clinical trials.

Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.

Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit.

An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011.

P2888

bjc.2015.477

P304

262-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2015.477

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Udai Banerji

P577

2016-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26757260

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4742590

http://www.w3.org/2001/XMLSchema#string

Phase I trial outcomes in older patients with advanced solid tumours

about

P2860

P2860

Phase I trial outcomes in older patients with advanced solid tumours

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932